| |
Cell therapy developers face many challenges as they transition from benchtop to bedside. Here we examine when and how to consider transitioning from research-use-only to animal-free (AF) and GMP critical reagents. Download now. 
|
|
Today’s Big NewsJul 1, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
| By Annalee Armstrong The slow quarter follows an exciting first one, in which pharma finally spent some of the trillions in cash hanging around for such transactions. |
|
|
|
By Nick Paul Taylor Bristol Myers Squibb is walking away from its $650 million bet on an Eisai antibody-drug conjugate (ADC). The Japanese drugmaker said BMS decided to end the co-development agreement as part of an ongoing portfolio prioritization push. |
By Conor Hale First reported by The San Diego Union-Tribune, the diabetes sensor maker said it plans to transition its HQ into an innovation center after previously housing commercial production and R&D. |
By Angus Liu Novartis recently said it will propose Bristol Myers Squibb's former chairman and CEO, Giovanni Caforio, to serve as its next board chair in 2025. Fierce Pharma explored the status of the industry's noncompete clauses with experts to learn whether an intercompany transition at the highest levels can proceed without a hitch. |
|
Dive into the cutting-edge world of recombinant antibody engineering, from optimizing your antibody plasmid to antibody maturation and humanization. Explore innovative techniques and strategies that enhance antibody efficacy, paving the way for breakthroughs in therapeutic development. Download now. 
|
|
By Kevin Dunleavy Less than three weeks after a group of cancer victims filed a motion attempting to block Johnson & Johnson's latest talc litigation bankruptcy plan—which comes with a $6.5 billion class-action settlement offer—a New Jersey federal court has quashed the effort. |
By Conor Hale Issues with ventilators across three major manufacturers—Philips, Baxter and Zoll—have led to a string of Class I recall notices from the FDA, the agency’s most severe level. |
By Kevin Dunleavy UniQure has sold its commercial viral vector manufacturing facility in Lexington, Mass., to Genezen, which will now supply uniQure’s clinical portfolio and produce CSL Behring’s hemophilia B gene therapy Hemgenix from the site. |
By Nick Paul Taylor Johnson & Johnson has presented phase 3 data on nipocalimab in generalized myasthenia gravis, providing a look at how its $6.5 billion prospect matches up to the approved FcRn rivals from argenx and UCB. |
By Joseph Keenan Stocks of cisplatin are now able to meet demand for the widely used chemotherapy drug that had been in short supply in the U.S. over the last year, the FDA's top official said. |
By James Waldron Eli Lilly is continuing to pursue its newfound passion for radiopharmaceuticals, this time handing Radionetics Oncology $140 million in upfront cash to partner on its pipeline of G protein-coupled receptor (GPCR) targeted drugs. |
By Nick Paul Taylor Eli Lilly has expanded its “Get Better” campaign, rolling out ads focused on its work to address inequities in access to dermatology diagnosis and treatment. |
Fierce podcasts Don’t miss an episode |
| In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years. |
|
|---|
|
|
|
Download this resource to accelerate your oncology clinical trials, optimize patient enrollment, and monitor minimal residual disease and molecular response effectively. Explore how this tissue-free, methylation-based technology enhances circulating tumor DNA (ctDNA) detection, enriching trial populations and evaluating therapy responses faster than tissue assays. 
|
|
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
eBook In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
